First DNA vaccine for dengue developed by India

Current Affairs

  • Researchers at India’s National Centre for Biological Sciences, in collaboration with nine other institutions in India, Africa, and the US, have developed India’s first and only DNA vaccine candidate for dengue fever.
  • In early tests on mice, it was shown to stimulate a stronger immune response and increase survival rates after exposure to disease.
  • In 2019, the dengue vaccine CYDTDV or Dengvaxia was approved by the US Food and Drug Administration, the first dengue vaccine to receive regulatory approval in the US.
  • Dengvaxia is basically a live, weakened dengue virus that is given as a dose to people in the age group of 9 to 16 years who have previously been diagnosed with dengue and live in infected areas.

Google search